Targeting prognostic proinflammatory biomarkers to improve outcome on IO drugs

Bibliographic Details
Main Author:	John Haanen
Format:	Article
Language:	English
Published:	Elsevier 2019-07-01
Series:	ESMO Open
Online Access:	https://esmoopen.bmj.com/content/4/4/e000557.full

id	doaj-38bad6b41e034eba9394f5b75b8ea022
record_format	Article
spelling	doaj-38bad6b41e034eba9394f5b75b8ea0222021-04-02T16:07:58ZengElsevierESMO Open2059-70292019-07-014410.1136/esmoopen-2019-000557Targeting prognostic proinflammatory biomarkers to improve outcome on IO drugsJohn Haanen0Medical Oncology, Nederlands Kanker Instituut - Antoni van Leeuwenhoek Ziekenhuis, Amsterdam, The Netherlands https://esmoopen.bmj.com/content/4/4/e000557.full
collection	DOAJ
language	English
format	Article
sources	DOAJ
author	John Haanen
spellingShingle	John Haanen Targeting prognostic proinflammatory biomarkers to improve outcome on IO drugs ESMO Open
author_facet	John Haanen
author_sort	John Haanen
title	Targeting prognostic proinflammatory biomarkers to improve outcome on IO drugs
title_short	Targeting prognostic proinflammatory biomarkers to improve outcome on IO drugs
title_full	Targeting prognostic proinflammatory biomarkers to improve outcome on IO drugs
title_fullStr	Targeting prognostic proinflammatory biomarkers to improve outcome on IO drugs
title_full_unstemmed	Targeting prognostic proinflammatory biomarkers to improve outcome on IO drugs
title_sort	targeting prognostic proinflammatory biomarkers to improve outcome on io drugs
publisher	Elsevier
series	ESMO Open
issn	2059-7029
publishDate	2019-07-01
url	https://esmoopen.bmj.com/content/4/4/e000557.full
work_keys_str_mv	AT johnhaanen targetingprognosticproinflammatorybiomarkerstoimproveoutcomeoniodrugs
_version_	1721557672191328256

Similar Items